MTAP Deletion

CI-VAR-00000646Explore in graph →CIViC 4585

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Urothelial Carcinoma1
MTAP Deletion	Pemetrexed	Predictive	B	Supports Sensitivity Response	2	submitted	EID12722 In a single-arm phase II trial of pemetrexed in previously treated metastatic urothelial carcinoma selected for MTAP deficiency by IHC (NCT02693717; n = 7), 3 patients (42%) achieved ORR, with median … (full text at CIViC) PMID 35379845 · Alhalabi et al., 2022 · Open in CIViC	civic
Solid Neoplasm1
MTAP Deletion	Anvumetostat	Predictive	B	Supports Sensitivity Response	3	accepted	EID12158 In this phase 1 trial, 80 patients harbouring MTAP deletions/CDKN2A deletions received AMG 193 in a dose escalation study. The most common tumour types were PDAC (23.8%), NSCLC (17.5%), biliary tract … (full text at CIViC) PMID 39293516 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.